Search

Search Constraints

You searched for: Author/Creator Benjamin, Reuben

Search Results

1. The combination of an inclusive novel agent treatment strategy, pre‐emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients. (12th March 2019)

2. Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. Issue 3 (17th March 2021)

3. Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience. (17th February 2017)

4. Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Issue 3 (29th December 2021)

5. Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Issue 6 (3rd May 2021)

6. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3. (2019)

7. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. (1st March 2021)

8. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience. (10th August 2020)